OTCMKTS:FSNUY - Fresenius SE & Co. KGaA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $44.65
  • Forecasted Upside: 419.27 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$8.60
▲ +0.052 (0.61%)

This chart shows the closing price for FSNUY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fresenius SE & Co. KGaA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FSNUY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FSNUY

Analyst Price Target is $44.65
▲ +419.27% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Fresenius SE & Co. KGaA in the last 3 months. The average price target is $44.65, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 419.27% upside from the last price of $8.60.

This chart shows the closing price for FSNUY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 polled investment analysts is to hold stock in Fresenius SE & Co. KGaA. This rating has held steady since December 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/13/2022JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral€34.50 ➝ €33.30
5/10/2022HSBCDowngradeBuy ➝ Hold
5/6/2022Credit Suisse GroupBoost Price Target€35.00 ➝ €38.00
2/28/2022Credit Suisse GroupLower Price TargetNeutral ➝ Neutral€43.00 ➝ €35.00
2/25/2022Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold€38.00 ➝ €36.00
2/25/2022Societe GeneraleLower Price TargetBuy ➝ Buy€94.00 ➝ €87.00
2/24/2022JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral€42.30 ➝ €34.50
2/16/2022Berenberg BankBoost Price TargetBuy ➝ Buy€55.95 ➝ €60.25
12/1/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
11/23/2021HSBCInitiated CoverageBuy
11/11/2021Jefferies Financial GroupUpgradeUnderperform ➝ Hold
11/9/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
10/26/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
9/10/2021BarclaysReiterated RatingOverweight
8/11/2021JPMorgan Chase & Co.Reiterated RatingOverweight
8/4/2021Societe GeneraleReiterated RatingBuy
8/2/2021Credit Suisse GroupReiterated RatingNeutral
7/23/2021BarclaysSet Price TargetOverweight$13.36
7/22/2021JPMorgan Chase & Co.Reiterated RatingOverweight
7/21/2021Morgan StanleyReiterated RatingOverweight
7/21/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
7/21/2021UBS GroupUpgradeNeutral
5/12/2021DZ BankReiterated RatingBuy
4/28/2021BarclaysReiterated RatingOverweight
2/19/2021Berenberg BankReiterated RatingBuy
2/10/2021JPMorgan Chase & Co.Reiterated RatingOverweight
2/4/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
2/3/2021DZ BankReiterated RatingBuy
2/2/2021BarclaysReiterated RatingOverweight
1/6/2021Nord/LBReiterated RatingBuy
12/3/2020Bank of AmericaDowngradeBuy ➝ Neutral
11/26/2020DZ BankReiterated RatingBuy
11/10/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/2/2020Morgan StanleyReiterated RatingOverweight
9/23/2020BarclaysUpgradeEqual Weight ➝ Overweight
8/14/2020JPMorgan Chase & Co.Reiterated RatingOverweight
8/5/2020Jefferies Financial GroupDowngradeHold ➝ Underperform
6/1/2020BarclaysReiterated RatingEqual Weight
5/20/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
5/19/2020JPMorgan Chase & Co.Reiterated RatingOverweight
4/27/2020BarclaysReiterated RatingEqual Weight
4/23/2020JPMorgan Chase & Co.Reiterated RatingOverweight
3/24/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform
11/12/2019Sanford C. BernsteinInitiated CoverageOutperform ➝ Market Perform
3/22/2019The Goldman Sachs GroupReiterated RatingBuy
3/7/2019Jefferies Financial GroupReiterated RatingHold
1/15/2019BarclaysDowngradeOverweight ➝ Equal Weight
1/9/2019UBS GroupUpgradeSell ➝ Neutral
12/18/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy
11/17/2017UBS GroupDowngradeNeutral ➝ Sell
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/24/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/25/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Fresenius SE & Co. KGaA logo
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Read More

Today's Range

Now: $8.60
Low: $8.47
High: $8.62

50 Day Range

MA: $9.06
Low: $8.50
High: $9.58

52 Week Range

Now: $8.60
Low: $7.37
High: $14.20

Volume

65,072 shs

Average Volume

116,639 shs

Market Capitalization

$19.21 billion

P/E Ratio

8.81

Dividend Yield

1.88%

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Fresenius SE & Co. KGaA?

The following Wall Street research analysts have issued reports on Fresenius SE & Co. KGaA in the last year: Barclays PLC, Berenberg Bank, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Societe Generale, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for FSNUY.

What is the current price target for Fresenius SE & Co. KGaA?

0 Wall Street analysts have set twelve-month price targets for Fresenius SE & Co. KGaA in the last year. Their average twelve-month price target is $44.65, suggesting a possible upside of 419.3%.
View the latest price targets for FSNUY.

What is the current consensus analyst rating for Fresenius SE & Co. KGaA?

Fresenius SE & Co. KGaA currently has 6 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FSNUY, but not buy more shares or sell existing shares.
View the latest ratings for FSNUY.

How do I contact Fresenius SE & Co. KGaA's investor relations team?

Fresenius SE & Co. KGaA's physical mailing address is Else-Kroner-Strasse 1, Bad Homburg 2M, 61352. The company's listed phone number is (496) 172-6080 and its investor relations email address is [email protected] The official website for Fresenius SE & Co. KGaA is www.fresenius.com. Learn More about contacing Fresenius SE & Co. KGaA investor relations.